ArticleCureus2026
Feasibility of Salvage Therapy With High-Dose Bendamustine and Rituximab Based on a Series of Two Cases From a Planned Phase II Trial for Relapsed/Refractory Diffuse Large B-cell Lymphoma.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHigh-dose chemotherapy combined with autologous hematopoietic stem cell transplantation (HDC/AHSCT) is an important option to improve the prognosis of relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL). Combination therapy of bendamustine and rituximab (BR120: 120 mg/m
methodsThis study involved patients treated at two institutions: the Department of Hematology, Iwate Prefectural Central Hospital (Iwate, Japan), and the Department of Hematology and Oncology, Japanese Red Cross Society Himeji Hospital (Hyogo, Japan). To evaluate the feasibility of HSC mobilization and the efficacy and safety of BR120 combined with G-CSF and plerixafor, we conducted a multicenter, open-label, phase II clinical study of BR120 salvage therapy in patients with R/R DLBCL indicated for HDC/AHSCT. Patients underwent HSC collection and continued BR120 therapy for up to four cycles. The expected number of patients enrolled in the 11 participating institutions is 20.
resultsOnly two patients were enrolled in the study. However, both also achieved a target harvest of 2×10
conclusionWe could achieve successful mobilization and stem cell collection with BR120 salvage therapy in two cases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.